Esperion Therapeutics Inc. (NASDAQ:ESPR) stock has reached a new 52-week high, touching $3.41, as investors rally behind the biopharmaceutical company known for its innovative cholesterol-lowering therapies. The company's robust performance is reflected in its impressive revenue growth of 187% over the last twelve months, with current revenue standing at $295.45 million. This peak represents a significant turnaround from previous performance, with the stock demonstrating a remarkable 1-year change, surging by 94.44%. The company's recent advancements and positive clinical trial results have instilled confidence among shareholders, propelling the stock to levels not seen in the past year and marking a period of robust gains for Esperion. According to InvestingPro analysis, the stock is currently trading above its Fair Value, with 13 additional ProTips available to help investors make informed decisions about this momentum stock.
In other recent news, Esperion Therapeutics has made significant strides in its operations. The company has seen notable revenue growth of 187% over the past year and has submitted New Drug Submissions to Health Canada for two cholesterol-lowering medications, NEXLETOL and NEXLIZET. Esperion's partner, Otsuka Pharmaceutical (TADAWUL:2070) Co., Ltd., has also submitted a New Drug Application to the Japanese Ministry of Health, Labour and Welfare for bempedoic acid, intended for patients with hypercholesterolemia and familial hypercholesterolemia.
The company's financial performance has been impressive, with a 53% year-over-year increase in U.S. net product revenue, totaling $31.1 million in the third quarter of 2024. Total (EPA:TTEF) revenue rose to $51.6 million, up from $34 million in the previous year. This growth was driven by the expansion of their product labels, strategic partnerships, and an expansion of payer coverage to over 165 million patient lives.
Esperion has also successfully monetized European royalties, repaid debts, and reported a 17% increase in total retail prescription equivalents. Despite facing gross-to-net headwinds, the company has expanded the labels for its products, NEXLETOL and NEXLIZET. These are recent developments that investors should monitor closely in the coming months.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.